See more : Chengdu Xuguang Electronics Co., Ltd. (600353.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Olema Pharmaceuticals, Inc. (OLMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olema Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nickel Industries Limited (NIC.AX) Income Statement Analysis – Financial Results
- The Home Depot, Inc. (HD) Income Statement Analysis – Financial Results
- Viad Corp (VVI) Income Statement Analysis – Financial Results
- Sanyo Chemical Industries Ltd. (4471.T) Income Statement Analysis – Financial Results
- VGTel, Inc. (VGTL) Income Statement Analysis – Financial Results
Olema Pharmaceuticals, Inc. (OLMA)
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| Gross Profit | -377.00K | -1.66M | -1.66M | -11.00K | -9.03K | -8.24K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.14M | 82.27M | 51.10M | 13.70M | 3.92M | 1.69M |
| General & Administrative | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Other Expenses | 0.00 | -27.00K | -47.00K | 0.00 | 0.00 | -31.00K |
| Operating Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Cost & Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Interest Income | 8.32M | 2.23M | 442.00K | 60.00K | 7.00K | 4.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 653.00K | 0.00 | 28.00K |
| Depreciation & Amortization | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| EBITDA | -104.58M | -103.13M | -69.43M | -21.52M | -4.31M | -2.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.96M | -106.99M | -71.49M | -21.53M | -4.32M | -2.08M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.31M | 2.20M | 395.00K | -593.00K | 7.00K | -118.00K |
| Income Before Tax | -96.66M | -104.79M | -71.10M | -22.12M | -4.32M | -2.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.20M | -210.00K | 642.00K | -155.86K | -90.00K |
| Net Income | -96.66M | -102.59M | -70.89M | -22.76M | -4.32M | -2.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| EPS Diluted | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| Weighted Avg Shares Out | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
| Weighted Avg Shares Out (Dil) | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Olema Oncology to Participate in Upcoming Investor Conferences in May
SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that its management team will participate...
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D.,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today reported financial results for the fourth quarter...
Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Molecular Cancer Therapeutics,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will participate in...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models
Source: https://incomestatements.info
Category: Stock Reports